

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on January 9, 2006

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1632
Patent Application
Docket No. USF-211XT
Serial No. 10/605,452

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Joanne Hama
Art Unit : 1632
Applicants : William G. Kerr, John M. Ninos
Serial No. : 10/605,452
Filed : September 30, 2003
Conf. No. : 2451
For : Novel SH2containing Inositol 5'-phosphatase Isoform That Partners With The Grb2 Adapter Protein

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicants have not submitted copies of the U.S. patents cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).


Included with this supplemental Information Disclosure Statement are copies of Office Actions issued in two co-pending applications, U.S. serial no. 09/955,174, filed September 19, 2001, and U.S. serial no. 10/097,101, filed March 14, 2002. As the file wrappers of these related

applications are available to the Examiner, unless requested by the Examiner, the applicants will not be submitting subsequent Office Actions from these co-pending applications.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (3 pages); copies of some references cited therein



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/605,452
Filing Date	September 30, 2003
First Named Inventor	William G. Kerr
Art Unit	1632
Examiner Name	Joanne Hama
Attorney Docket Number	USF-211XT

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-6,506,559 B1	01-14-2003	Fire et al.	All
	U2	US-5,804,412	09-08-1998	Gill et al.	All
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	WO 99/32619 A1	07-01-1999	Carnegie Inst. of Wash.	All	
	F					
	F					
	F					
	F					
	F					
	F					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/605,452
				Filing Date	September 30, 2003
				First Named Inventor	William G. Kerr
				Group Art Unit	1632
				Examiner Name	Joanne Hama
				Attorney Docket Number	USF-211XT
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BONETTA, L. "RNAi: Silencing never sounded better" <i>Nature Methods</i> , 2004, 1(1):79-86.	
	R2	CAPLEN, N.J. "RNAi as a gene therapy approach" <i>Expert Opin. Biol. Ther.</i> , 2003, 3:575-586.	
	R3	CAPLEN, N.J. <i>et al.</i> "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems" <i>PNAS</i> , 2001, 98(17):9742-9747.	
	R4	DAMEN, J.E. <i>et al.</i> "The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase" <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 93:1689-1693.	
	R5	ELBASHIR, S. <i>et al.</i> "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells" <i>Nature</i> , 2001, 411:494-498.	
	R6	ELBASHIR, S. <i>et al.</i> "RNA interference is mediated by 21- and 22-nucleotide RNAs" <i>Genes & Development</i> , 2001, 15:188-200.	
	R7	FIRE, A. <i>et al.</i> "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> " <i>Nature</i> , 1998, 391:806-811.	
	R8	HARBORTH, J. <i>et al.</i> "Identification of essential genes in cultured mammalian cells using small interfering RNAs" <i>J. Cell Sci.</i> , Dec. 2001, 114(Pt. 24):4557-4565.	
	R9	LIU, Q. <i>et al.</i> "Molecular cloning and chromosomal localization in human and mouse of the SH2-containing inositol phosphatase, INPP5D (SHIP)" <i>Genomics</i> , 1997, 39:109-112.	
	R10	MONTGOMERY, M.K. <i>et al.</i> "RNA as a target of double-stranded RNA-mediated genetic interference in <i>Caenorhabditis elegans</i> " <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 95:15502-15507.	
	R11	SVOBODA, P. <i>et al.</i> "Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference" <i>Development</i> , 2000, 127:4147-4156.	
	R12	TUSCHL, T. <i>et al.</i> "RNA interference and small interfering RNAs" <i>ChemBiochem</i> , 2001, 2(4):239-245.	
	R13	TUSCHL, T. <i>et al.</i> "Targeted mRNA degradation by double-stranded RNA in vitro" <i>Genes & Development</i> , 1999, 13:3191-3197.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/605,452	
			Filing Date	September 30, 2003	
			First Named Inventor	William G. Kerr	
			Group Art Unit	1632	
			Examiner Name	Joanne Hama	
			Attorney Docket Number	USF-211XT	
Sheet	3	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	WARE, M.D. <i>et al.</i> "Cloning and characterization of human SHIP, the 145-kD inositol 5-phosphatase that associates with SHC after cytokine stimulation" <i>Blood</i> , 1996, 88:2833-2840.	
	R15	ZAMORE, P. <i>et al.</i> "RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals" <i>Cell</i> , 2000, 101:25-33.	
	R16	Office Action mailed 12/29/2005 in U.S. Serial No. 09/955,174, filed September 19, 2001.	
	R17	Office Action mailed 08/29/05 in U.S. Serial No. 10/097,101, filed March 14, 2002.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.